

December 11, 1964

Daniel H. Efron, M.D., Ph.D.
Program Director in Pharmacology
Psychopharmacology Service Center
National Institutes of Mental Health
Bethesda, Maryland 20014

Dear Dr. Efron:

With regard to Synhexyl, I have reviewed the information which you sent to me and we are interested in undertaking a clinical assessment of this drug in the immediate future. Dr. Gershon and I are in the process of writing a small grant application to provide some additional funds for the pre-clinical assessment, but our ward assessments can be undertaken in the near future.

However, before doing so I would be grateful if we could have copies of any toxicity information so that I can make this available to the pharmacology committee of this center. Am I to inquire for this from you, or from a representative of the parent company? If the latter, would you please advise me to whom to write.

Secondly, when this information is available, am I to contact you for supplies of Synhexyl or to someone else?

Thank you for your cooperation.

Sincerely yours,

Max Fink, M.D.
Director

mf;ls